stoxline Quote Chart Rank Option Currency Glossary
Kala Pharmaceuticals, Inc. (KALA)
7.08  0.22 (3.21%)    07-23 16:00
Open: 6.92
High: 7.08
Volume: 17,004
Pre. Close: 6.86
Low: 6.62
Market Cap: 20(M)
Technical analysis
2024-07-23 4:53:20 PM
Short term     
Mid term     
Targets 6-month :  9.2 1-year :  10.75
Resists First :  7.88 Second :  9.2
Pivot price 7.14
Supports First :  5.61 Second :  4.21
MAs MA(5) :  7.02 MA(20) :  6.84
MA(100) :  6.91 MA(250) :  8.08
MACD MACD :  0.2 Signal :  0.2
%K %D K(14,3) :  35 D(3) :  43.1
RSI RSI(14): 53.9
52-week High :  15.93 Low :  4.21
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ KALA ] has closed above bottom band by 45.5%. Bollinger Bands are 3.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.09 - 7.13 7.13 - 7.16
Low: 6.54 - 6.58 6.58 - 6.61
Close: 7.01 - 7.08 7.08 - 7.14
Company Description

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Headline News

Thu, 28 Mar 2024
symbol__ Stock Quote Price and Forecast - CNN

Wed, 02 Aug 2023
Kala Pharmaceuticals Announces Name Change to KALA BIO - Yahoo Finance

Thu, 13 Jul 2023
Kala Pharmaceuticals' KPI-012: A Novel Orphan Drug Therapy For PCED - Seeking Alpha

Thu, 13 Apr 2023
Kala’s KPI-012 secures FDA Fast Track status to treat PCED - Pharmaceutical Technology

Wed, 28 Dec 2022
Why Is Kala Pharmaceuticals (KALA) Stock Soaring 240%? - InvestorPlace

Wed, 28 Dec 2022
Kala Pharmaceuticals shares soar after FDA approves trial for drug to treat PCED - CBS News

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 4 (M)
Shares Float 2 (M)
Held by Insiders 5.4 (%)
Held by Institutions 40.2 (%)
Shares Short 295 (K)
Shares Short P.Month 8 (K)
Stock Financials
EPS -14.57
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.36
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -40.8 %
Return on Equity (ttm) -262.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -9.1
Qtrly Earnings Growth 0 %
Operating Cash Flow -29 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -0.49
PEG Ratio -0.1
Price to Book value 2.98
Price to Sales 0
Price to Cash Flow -1.09
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android